Results 51 to 60 of about 28,574 (227)

Fludarabine induces apoptosis in chronic lymphocytic leukemia - the role of P53, Bcl-2, Bax, Mcl-1, and Bag-1 proteins [PDF]

, 2006
The expression of P53, Bcl-2, Bax, Bag-1, and Mcl-1 proteins in CD5/CD20-positive B-chronic lymphocytic leukemia (B-CLL) cells from 30 typical CLL patients was evaluated before and after 48 h of incubation with 10-6 M fludarabine using multiparametric ...
Faria, Jose Roberto de, Faria, Rosa Malena Delbone de, Kerbauy, José, Oliveira, José Salvador Rodrigues de, Yamamoto, Mihoko   +4 more
core   +2 more sources

Evidence and Equity Gaps in Clinical Care of Chronic Lymphocytic Leukaemia in Portugal: A Real‐World, Multicentre, Cohort Study

eJHaem, Volume 7, Issue 2, April 2026.
ABSTRACT Objectives Targeted therapies have markedly improved outcomes in chronic lymphocytic leukaemia (CLL), particularly among patients with TP53 alterations and unmutated IGHV. However, real‐world studies report persistent inequalities in access to optimal care.
Susana Esteves, Inês Coelho, José Carda, Sara Duarte, Inês Carvalhais, Daniela Alves, Rita Coutinho, Maria Gomes da Silva   +7 more
wiley   +1 more source

Co‐inheritance of ITGA2B and TUBB1 variants in a family reveals distinct genetic contributions to platelet dysfunction

British Journal of Haematology, EarlyView.
Perla Bandini, Nina Borràs, Laura Martin‐Fernandez, Nuria Fernández‐Mosteirín, Maria Reyes Aguinaco, Olga Benítez, Natàlia Comes, Lorena Ramírez, Noemí González, Carina Lera, Carme Altisent, Francisco Vidal, Irene Corrales   +12 more
wiley   +1 more source

Safety and Efficacy of Damoctocog Alfa Pegol in Previously Treated Children Aged 7 to < 12 Years With Severe Haemophilia A in the Phase 3, Open Label Alfa‐PROTECT Main Study

European Journal of Haematology, Volume 116, Issue 4, Page 435-442, April 2026.
ABSTRACT Background In the earlier PROTECT VIII Kids study (NCT01775618), damoctocog alfa pegol was efficacious for prevention and treatment of bleeds in children aged < 12 years with severe haemophilia A. Objective Assess the safety of damoctocog alfa pegol, including hypersensitivity and loss of efficacy (LoE) due to an immune response to ...
Margareth C. Ozelo, Matteo Luciani, Heidi Glosli, Kaan Kavakli, Nasrin Samji, Gregory C. Makris, Claudia Tueckmantel, Monika Maas Enriquez, Luciana C. Oliveira, Shveta Gupta, Mario Guillermo Arbesú, Mauro Davoli, Anthony K. C. Chan, Maria E. Mancuso   +13 more
wiley   +1 more source

Contribuição para o controlo da infeção nosocomial de Candida parapsilosis por tipagem com marcadores de DNA microssatélite [PDF]

, 2013
Fungal infections constitute a relevant problem in hospitals from all over the world. Their easy transmission through the air, water, or by direct or indirect contact with contaminated persons, surfaces or objects lead to an increasing preoccupation ...
Pais, C., Sabino, R., Sampaio, P., Veríssimo, C., Viegas, C.   +4 more
core  

Acute lymphoblastic leukemia in Down syndrome and TEL/AML1(ETV6/RUNX1) [PDF]

, 2009
Universidade Federal de São Paulo (UNIFESP), Escola Paulista de Medicina (EPM)Fleury - Medicina e SaúdeUNIFESP ...
Chauffaille, Maria de Lourdes Lopes Ferrari
core   +3 more sources

Plain Language Summary on Safety and Efficacy of Damoctocog Alfa Pegol in Previously Treated Children Aged 7 to < 12 Years With Severe Haemophilia A in the Phase 3, Open Label Alfa‐PROTECT Main Study

European Journal of Haematology, Volume 116, Issue 4, Page 471-472, April 2026.
ABSTRACT This is a plain language summary describing results from the Alfa‐PROTECT study on safety and efficacy of damoctocog alfa pegol in previously treated children aged between 7 and 12 years with severe haemophilia A.
Margareth C. Ozelo, Matteo Luciani, Heidi Glosli, Kaan Kavakli, Nasrin Samji, Gregory C. Makris, Claudia Tueckmantel, Monika Maas Enriquez, Luciana C. Oliveira, Shveta Gupta, Mario Guillermo Arbesú, Mauro Davoli, Anthony K. C. Chan, Maria Elisa Mancuso   +13 more
wiley   +1 more source

Modifiers factors of clinical severity in sickle cell anemia [PDF]

, 2007
Sickle cell anemia is a heterogeneous disorder with different degrees of clinical severity despite of being caused by a single base pair mutation (Glu6Val) of the ß-globin gene.
Figueiredo, Maria Stella
core   +3 more sources

Predicting Chronicity in Children and Adolescents With Newly Diagnosed Immune Thrombocytopenia at the Timepoint of Diagnosis Using Machine Learning‐Based Approaches

Pediatric Blood &Cancer, Volume 73, Issue 3, March 2026.
ABSTRACT Objectives To identify predictors of chronic ITP (cITP) and to develop a model based on several machine learning (ML) methods to estimate the individual risk of chronicity at the timepoint of diagnosis. Methods We analyzed a longitudinal cohort of 944 children enrolled in the Intercontinental Cooperative immune thrombocytopenia (ITP) Study ...
Severin Kasser, Alice Bizeul, Meera Chitlur, Hugo Donato, Jelena Roganovic, Julia E. Vogt, Thomas Kühne   +6 more
wiley   +1 more source

Prospective validation of podoplanin expression as a diagnostic biomarker of acute promyelocytic leukemia

Cytometry Part B: Clinical Cytometry, Volume 110, Issue 2, Page 128-133, March 2026.
Abstract Acute promyelocytic leukemia (APL) is a medical emergency that needs immediate diagnosis and treatment. Podoplanin, a transmembrane glycoprotein that binds CLEC‐2 on platelets, was recently demonstrated to be abnormally expressed in leukemic blasts in APL, as opposed to other forms of AML, in a study using thawed primary cells.
Camilla Maria de Alencar Saraiva, Carla Roberta Peachazepi Moraes, Bruno Kosa Lino Duarte, Gislaine Borba Oliveira, Herton Luiz Alves Sales Filho, Paula de Melo Campos, Sara Teresinha Olalla Saad, Erich Vinicius De Paula   +7 more
wiley   +1 more source